Delivery Order SPE2DB22D2007-SPE2DB25FJ5FR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $34,983.20 on September 4, 2025, for Zepbound (semaglutide) 5 mg/0.5 mL pens with a completion date of September 5, 2025. This is a firm fixed-price, non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,298.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside contract, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency awarded a delivery order valued at $18,697.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on June 27, 2025, with a completion date of June 30, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,785.59 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order represents part of AmerisourceBergen's broader pharmaceutical supply operations supporting federal medical procurement needs. The company, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,235.08 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a $32,717.50 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 8, 2025, with an ultimate completion date of September 9, 2025. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The contract was fulfilled from the...
- The Defense Logistics Agency awarded a $38,195.64 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pens in 0.5 mL quantities. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by September 18, 2025. The contract will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5FRDelivery Order
The Defense Logistics Agency (DLA) awarded a $15,640.67 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on September 23, 2025, with completion expected by September 24, 2025. This award was made without a set-aside designation, indicating open competition. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and federal procurement operations. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies military and veteran healthcare systems across multiple therapeutic domains, including specialty medications, diabetes treatments, and other essential pharmaceuticals. The company's inclusion in DLA's Pharmaceutical Prime Vendor Global Program Generation V demonstrates its strategic role in supporting Defense Health Agency operations and broader federal healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.6k | 9/23/25 |